Key Data
Fresenius is one of the top 30 companies in Germany in terms of market capitalization. It is included in Germany's leading index, the DAX, as well as the Prime Standard Pharma & Healthcare Index, and the Dow Jones Stoxx 600 Healthcare Index. We are also listed in the Dow Jones Euro Stoxx and the FTSE Eurofirst 300 indices.
The Fresenius ordinary shares are traded on the Official Market at the stock exchanges in Frankfurt, Düsseldorf and Munich.
Fresenius SE & Co. KGaA's capital stock currently amounts to 163.3 €m (January 31, 2012). The shares are notional no-par-value shares. Each share represents € 1.00 of the capital stock.
Basic Share Information
| Ordinary share | |
| Securities code no. | 578 560 |
| Ticker symbol | FRE |
| ISIN | DE0005785604 |
| Bloomberg symbol | FRE GR |
| Reuters symbol | FREG.de |
Key Data
|
2010 |
2009 |
2008 |
2007 |
2006 |
|
| Number of shares1) |
162,450,090 |
161,315,376 |
161,143,734 |
155,164,770 |
51,451,292 |
| Stock exchange quotation ordinary share2) (€) | |||||
| High |
67.59 |
43.76 |
60.87 |
63.35 |
51.323) |
| Low |
41.80 |
27.69 |
31.93 |
50.17 |
35.473) |
| Year-end quotation |
62.75 |
43.45 |
36.23 |
56.00 |
50.573) |
| Market capitalization4) (million €) |
10,301 |
7,538 |
6,270 |
8,759 |
8,091 |
| Total dividend distribution (million €) |
139.7 |
121.8 |
113.6 |
103.2 |
88.8 |
| Per share in €1) | |||||
| Dividend ordinary share |
0.86 |
0.75 |
0.70 |
0.66 |
0.57 |
| Dividend preference share |
n.a. |
0.76 |
0.71 |
0.67 |
0.58 |
| Earings per ordinary share |
4.085) |
3.185) |
2.856) |
2.64 |
2.153) |
| Earnings per preference share |
4.085) |
3.195) |
2.866) |
2.65 |
2.163) |
1) Equally divided into ordinary shares and prefernce shares until January 28, 2011
2) Xetra closing prices on the Frankfurt Stock Exchange
3) Adjusted for share split in February 2007
4) Total number of shares multiplied by the respective Xetra year-end quotation on the Frankfurt Stock Exchange
5) Adjusted for special items resulting from changes in the market value (mark-to-market accounting) of the Mandatory Exchangeable Bonds (MEB) and the Contingent Value Rights (CVR) in connection with the acquisition of APP Pharmaceuticals
6) Before special items relating to the APP acquisition